mRNA-3210 clinical trials

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria

This study is testing a new messenger RNA (mRNA) medicine called mRNA-3210 for people with Phenylketonuria (PKU). Researchers want to see if it's safe, how much of it stays in the body, and how it affects PKU. It's an early-stage study, meaning it's one of the first times it's being given to humans.